| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 143, Issue 11 3470-3475, Copyright © 1989 by American Association of Immunologists
ARTICLES |
DC Brennan, MA Yui, RP Wuthrich and VE Kelley
Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.
TNF and IL-1 are potent immunologic and inflammatory cytokines. We have previously reported increased levels of mRNA for TNF alpha and IL-1 beta in MRL-lpr mice with lupus nephritis. To determine whether the increased levels of TNF and IL-1 mRNA are a more general feature of mice with lupus nephritis we studied cytokine gene expression in female NZB x NZW F1 (NZB/W) mice by Northern blot analysis. Enhanced steady state levels of mRNA for TNF alpha and IL-1 beta, but not IL-1 alpha, were detected in the renal cortices of animals with lupus nephritis. To determine whether administration of TNF or IL-1 would accelerate renal injury and mortality, we injected murine rTNF alpha or rIL-1 alpha i.p. into female NZB/W or C3H/FeJ mice at two doses, 2.0 micrograms or 0.2 micrograms, three times weekly for 2 or 4 mo beginning at 2 or 4 mo of age. Administration of the lower dose of each cytokine accelerated renal disease and mortality rate when treatment was initiated at 4 mo of age. At the higher dose, neither cytokine promoted disease. Treatment administered from 2-4 mo of age did not accelerate renal disease. This observation suggests that in order to cause renal injury, these cytokines must interact with other pathologic features present in these animals after 4 mo of age. These findings support the hypothesis that TNF and IL-1 can contribute to nephritis in murine models of lupus. Taken together with previously published data, we propose that TNF and IL-1 have differential dose effects on renal disease. The dose of TNF and IL-1 and the stage of disease activity dictate the pathogenic action of these cytokines.
This article has been cited by other articles:
|
|
 |
|
  L. Schiffer, R. Bethunaickan, M. Ramanujam, W. Huang, M. Schiffer, H. Tao, M. M. Madaio, E. P. Bottinger, and A. Davidson Activated Renal Macrophages Are Markers of Disease Onset and Disease Remission in Lupus Nephritis J. Immunol., February 1, 2008; 180(3): 1938 - 1947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Ryan and G. R. McLemore Jr. Hypertension and impaired vascular function in a female mouse model of systemic lupus erythematosus Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2007; 292(2): R736 - R742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Ryan, G. R. McLemore Jr, and S. T. Hendrix Insulin Resistance and Obesity in a Mouse Model of Systemic Lupus Erythematosus Hypertension, November 1, 2006; 48(5): 988 - 993. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Zeller, J. Hirahashi, A. Schwarting, A. H. Sharpe, and V. R. Kelley Inducible Co-Stimulator Null MRL-Faslpr Mice: Uncoupling of Autoantibodies and T Cell Responses in Lupus J. Am. Soc. Nephrol., January 1, 2006; 17(1): 122 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yung, R. C.W. Tsang, Y. Sun, J. K.H. Leung, and T. M. Chan Effect of Human Anti-DNA Antibodies on Proximal Renal Tubular Epithelial Cell Cytokine Expression: Implications on Tubulointerstitial Inflammation in Lupus Nephritis J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3281 - 3294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Subramanian, Y.-S. Yim, K. Liu, K. Tus, X. J. Zhou, and E. K. Wakeland Epistatic Suppression of Systemic Lupus Erythematosus: Fine Mapping of Sles1 to Less Than 1 Mb J. Immunol., July 15, 2005; 175(2): 1062 - 1072. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J S Smolen, G Steiner, and M Aringer Anti-cytokine therapy in systemic lupus erythematosus Lupus, March 1, 2005; 14(3): 189 - 191. [Abstract] [PDF]
|
|
|
|
|
|
M Aringer and J S Smolen Cytokine expression in lupus kidneys Lupus, January 1, 2005; 14(1): 13 - 18. [Abstract] [PDF]
|
|
|
|
|
|
M Aringer and J S Smolen Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention Lupus, May 1, 2004; 13(5): 344 - 347. [Abstract] [PDF]
|
|
|
|
|
|
K Hasegawa and T Hayashi Synthetic CpG oligodeoxynucleotides accelerate the development of lupus nephritis during preactive phase in NZB xNZWF1 mice Lupus, November 1, 2003; 12(11): 838 - 845. [Abstract] [PDF]
|
|
|
|
|
|
J.-Q. Yang, A. K. Singh, M. T. Wilson, M. Satoh, A. K. Stanic, J.-J. Park, S. Hong, S. D. Gadola, A. Mizutani, S. R. Kakumanu, et al. Immunoregulatory Role of CD1d in the Hydrocarbon Oil-Induced Model of Lupus Nephritis J. Immunol., August 15, 2003; 171(4): 2142 - 2153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sorensson, A. Bjornson, M. Ohlson, B. J. Ballermann, and B. Haraldsson Synthesis of sulfated proteoglycans by bovine glomerular endothelial cells in culture Am J Physiol Renal Physiol, February 1, 2003; 284(2): F373 - F380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Aringer, E Feierl, G Steiner, G H Stummvoll, E Hofler, C W Steiner, I Radda, J S Smolen, and W B Graninger Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death Lupus, February 1, 2002; 11(2): 102 - 108. [Abstract] [PDF]
|
|
|
|
|
|
C. S. Via, A. Shustov, V. Rus, T. Lang, P. Nguyen, and F. D. Finkelman In Vivo Neutralization of TNF-{alpha} Promotes Humoral Autoimmunity by Preventing the Induction of CTL J. Immunol., December 15, 2001; 167(12): 6821 - 6826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Meldrum, D. R. Meldrum, K. L. Hile, E. B. Yerkes, A. Ayala, M. P. Cain, R. C. Rink, A. J. Casale, and M. A. Kaefer p38 MAPK mediates renal tubular cell TNF-{alpha} production and TNF-{alpha}-dependent apoptosis during simulated ischemia Am J Physiol Cell Physiol, August 1, 2001; 281(2): C563 - C570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V N Foltyn and T D Golan In vitro ultraviolet irradiation induces pro-inflammatory responses in cells from premorbid SLE mice Lupus, April 1, 2001; 10(4): 272 - 283. [Abstract] [PDF]
|
|
|
|
|
|
R Segal, M Dayan, H Zinger, and E Mozes Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNF{alpha} monoclonal antibody and by pentoxiphylline Lupus, January 1, 2001; 10(1): 23 - 31. [Abstract] [PDF]
|
|
|
|
 |
|
 J. R. Toro, D. Finlay, X. Dou, S. C. Zheng, P. E. LeBoit, and M. K. Connolly Detection of Type 1 Cytokines in Discoid Lupus Erythematosus Arch Dermatol, December 1, 2000; 136(12): 1497 - 1501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S Dean, J. Tyrrell-Price, E. Crawley, and D. A Isenberg Cytokines and systemic lupus erythematosus Ann Rheum Dis, April 1, 2000; 59(4): 243 - 251. [Full Text]
|
|
|
|
|
|
J. F. McHale, O. A. Harari, D. Marshall, and D. O. Haskard TNF-{alpha} and IL-1 Sequentially Induce Endothelial ICAM-1 and VCAM-1 Expression in MRL/lpr Lupus-Prone Mice J. Immunol., October 1, 1999; 163(7): 3993 - 4000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yamamoto and D. J. Loskutoff Extrahepatic Expression and Regulation of Protein C in the Mouse Am. J. Pathol., August 1, 1998; 153(2): 547 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schwarting, T. Wada, K. Kinoshita, G. Tesch, and V. Rubin Kelley IFN-{gamma} Receptor Signaling Is Essential for the Initiation, Acceleration, and Destruction of Autoimmune Kidney Disease in MRL-Faslpr Mice J. Immunol., July 1, 1998; 161(1): 494 - 503. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
